

PTO/SB/08A (10-01)

Approved for use through 10/31/2002 OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet

1

of

		Complete if Known	
Application Number	10/084,639		
Filing Date	February 25, 2002		
First Named Inventor	Hageman, Gregory S., et. al.		
Art Unit	1644		
Examiner Name	Not yet assigned		
	Attorney Docket Number	020618-000920US	

### U.S. PATENT DOCUMENTS

Examiner	Cite No. <sup>1</sup>	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number Kind Code <sup>2</sup> (if known)			
✓	A1	US-5,472,939	12-05-1995	Fearon, et al	
	A2	US-5,681,571	10-28-1997	Holmgren et al.	
	A3	US-5,773,573	08-30-1998	Holms	
	A4	US-5,843,449	12-01-1998	Boots et al.	
	A5	US-5,951,984	09-14-1999	Kaneko et al.	
	A6	US-6,087,120	07-11-2000	Van Oeveren et al.	
	A7	US-6,103,235	08-15-2000	Neville et al.	
	A8	US-6,153,203	11-28-2000	Holmgren et al.	
	A9	US-2002/0015957 A1	02-07-2002	Hageman et al.	

### FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document			Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Country Code <sup>3</sup>	Number <sup>4</sup>	Kind Code <sup>5</sup> (if known)				
✓	B1	PCT	WO 90/15152	A1	12-13-1990			
	B2	PCT	WO 95/17673	A	06-29-1995			
	B3	PCT	WO 00/52479	A2	09-08-2000			<input type="checkbox"/>

Examiner  
Signature

David A. Saunders

Date  
Considered

6/18/04

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Kind Codes of U.S. Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.  
DE 7089919 v1

AUG 12 2003

PTO/SB/08B (10-01)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 2 of 9

## Complete if Known

Application Number	10/084,639
Filing Date	February 25, 2002
First Named Inventor	Hageman, Gregory S., et. al.
Art Unit	1644
Examiner Name	Not yet assigned

Attorney Docket Number 020618-000920US

## OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
<i>Aug</i>	C1	ABRAHA, A. and LUZIO, J.; "Inhibition of the formation of the complement membrane-attack complex by a monoclonal antibody to the complement component C8a Subunit", <i>Biochem J</i> 1989, pp. 933-8; 264, Great Britain.	
	C2	AKIYAMA, H. et al; "Inflammation and Alzheimer's disease"; <i>Neurobiology of Aging</i> 21; May-June 2000; pp. 383-421; Volume 21, No. 3	
	C3	ALLIKMETS, R. et al; "Mutation of the Stargardt Disease Gene (ABCR) in Age-Related Macular Degeneration", <i>Science</i> , September 19, 1997; pp. 1805-1807, Vol. 277	
	C4	AUDA, G. et al; "Measurement of complement activation products in patients with chronic rheumatic diseases", <i>Rheumatology International</i> ; 1990, 10(5):pp. 185-189, Springer-Verlag	
	C5	BAATRUP, G. et al; "Effects of coagulation temperature on measurements of complement function in serum samples from patients with systemic lupus erythematosus", <i>Annals of Rheumatic Disease</i> ; 1992, 51(7):892-897	
	C6	BACHINSKY, D. et al; "Detection of Two Forms of GP330", <i>American Journal of Pathology</i> ; August 1993, pp. 598-611, Vol. 143, No. 2	
	C7	BHKADI, S. & TRANUM-JENSEN, J.; "Membrane Damage by Complement", <i>Biochimica et Biophysica Acta</i> ; 1983, pp. 343-372; 737, Elsevier Science Publishers B.V.	
	C8	BORA, N.S. et al.; "Differential expression of the complement regulatory proteins in the human eye", <i>Investigative Ophthalmology &amp; Visual Science</i> ; December 1993, pp. 3579-3584, Vol. 34, No. 13	
	C9	BRALEY-MULLEN; "Activation of Distinct Subsets of T Suppressor Cells with Type III Pneumococcal Polysaccharide Coupled to Syngeneic Spleen Cells", <i>Immunological Tolerance To Self and Non-Self</i> , Annals of New York Academy of Science, 1982, pp. 156-166, Vol. 392.	
	C10	BURGER, R. et al; "The C Terminus of the Anaphylatoxin C3a Generated Upon Complement Activation Represents a Neoantigenic Determinant with Diagnostic Potential", <i>Journal of Immunology</i> , July 15, 1988; pp. 553-558, Vol. 141, No. 2, Printed in the U.S.A.	
	C11	BUYON, J. et al; "Assessment of Disease Activity and Impending Flare in Patients with Systemic Lupus Erythematosus", <i>Arthritis and Rheumatism</i> ; September 1992, pp. 1028-1037, Vol. 35, No. 9	
	C12	CAMPBELL, R. et al; "An Anion Binding Study of Vanadyl(IV) Human Serotransferrin", <i>Journal of Biological Chemistry</i> ; 1977, pp. 5996-6001, Vol. 252, No. 17, Printed in the U.S.A.	
	C13	CARAHHER, E.M. et al; "Evidence for enhanced rates of complement activation in serum from patients with newly diagnosed insulin-dependent diabetes mellitus exposed to rat islet cells and complement-dependent induction of islet cell apoptosis.", <i>Journal of Endocrinology</i> , 1999, pp. 143-153, Vol. 162, No. 1, Printed in Great Britain	
	C14	CHENOWETH, D. et al; "Complement Activation During Cardiopulmonary Bypass", <i>New England Journal of Medicine</i> ; February 26, 1981; pp. 497-502, Vol. 304, No. 9, Printed in the U.S.A.	

Examiner Signature

*David U. Saunders*

Date Considered

6/17/04

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

DE 7089919 v1

AUG 12 2003

PTO/SB/08B (10-01)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet

3 of 9

## Complete If Known

Application Number	10/084,639
Filing Date	February 25, 2002
First Named Inventor	Hageman, Gregory S., et. al.
Art Unit	1644
Examiner Name	Not yet assigned

Attorney Docket Number 020618-000920US

## OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
✓	C15	CHAIN, B. et al; "Improvement of the in vitro T cell proliferation assay by a modified method that separates the antigen recognition and IL-2-dependent steps.", <i>Journal of Immunological Methods</i> ; 1987, pp. 221-228, Vol. 99.	
✓	C18	DEBROCK, S. and DECLERCK, P.; "Characterization of common neoantigenic epitopes generated in plasminogen activator inhibitor-1 after cleavage of the reactive center loop or after complex formation with various serin proteinases.", <i>FEBS Letters</i> ; 1995, pp.243-246, Vol. 378.	
✓	C17	DELORI, F. and BEN-SIRA, I.; "Excitation and emission spectra of fluorescein dye in the human ocular fundus.". <i>Investigative Ophthalmology</i> ; June 1975, pp.487-492, Vol 14, No. 6.	
✓	C18	DELORI, F. et al; "In Vivo Fluorescence of the Ocular Fundus Exhibits Retinal Pigment Epithelium Lipofuscin Characteristics", <i>Investigative Ophthalmology &amp; Visual Science</i> ; March 1995, pp. 718-729, Vol. 36, No. 3.	
✓	C19	DETTRICK, B. et al.; "Class II Antigen Expression and Gamma Interferon Modulation of Monocytes and Retinal Pigment Epithelial Cells from Patients with Retinitis Pigmentosa", <i>Clinical Immunology and Immunopathology</i> , August 1985, pp. 201-211, Vol. 38, No. 2, San Diego, CA, U.S.A.	
✓	C20	EDWARDS, A. et al; "Malattia Leventinese: Refinement of the Genetic Locus and Phenotypic Variability in Autosomal Dominant Macular Drusen", <i>American Journal of Ophthalmology</i> ; September 1998, pp. 417-424, Vol. 126, Elsevier Science Inc.	
✓	C21	EGERTON, M. et al; "Identification of Ezrin as an 81-kDa Tyrosin-Phosphorylated Protein in T Cells", <i>The Journal of Immunology</i> , September 15, 1992, pp. 1847-1852, Vol. 149, No. 6, Printed in the U.S.A.	
✓	C22	ENK, C. et al; "A Standardized Human T-lymphocyte Proliferation Assay for Detecting Soluble Accessory Factors From Monocytes", <i>Acta Pathol Microbiol Immunol Scand [C]</i> , 1984, pp. 93-100, Vol. 92, No. 2.	
✓	C23	EPSTEIN, G.A. and RABB, M.F.; "Adult vitelliform macular degeneration: diagnosis and natural history"; <i>British Journal of Ophthalmology</i> ; 1980, pp. 733-40, Vol. 64.	
✓	C24	FELBOR, U. et al; "Adult vitelliform Macular Dystrophy Is Frequently Associated With Mutations in the Peripherin/RDS Gene", <i>Human Mutation</i> ; 1997, pp. 301-309, Vol. 10.	
✓	C25	FELBOR, U. et al; "Autosomal Recessive Sorsby Fundus Dystrophy Revisited: Molecular Evidence for Dominant Inheritance", <i>American Journal of Human Genetics</i> ; 1997, pp.57-62, Vol. 60.	
✓	C26	FITZGIBBON, J. et al; "Localisation of the human blue cone pigment gene to chromosome band 7q31.3-32", <i>Human Genetics</i> ; 1994, pp. 79-80, Vol. 93.	
✓	C27	FORSTROM, J.W. et al; Immunization to a syngeneic sarcoma by a monoclonal auto-anti-idiotypic antibody", <i>Nature</i> ; June 16, 1983; pp. 627-629, Vol. 303.	
✓	C28	GILTAY, R. et al; "Sequence, Recombinant Expression and Tissue Localization of Two Novel Extracellular Matrix Proteins, fibulin-3 and fibulin-4", <i>Matrix Biol</i> , October 1999, pp. 469-480, Vol. 18, No. 5.	

Examiner  
Signature

David A Saunders

Date  
Considered

6/17/04

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

DE 7089919 v1



Substitute for form 1449B/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet

4

of 9

### Complete if Known

Application Number	10/084,639
Filing Date	February 25, 2002
First Named Inventor	Hageman, Gregory S., et. al.
Art Unit	1644
Examiner Name	Not yet assigned

Attorney Docket Number 020618-000920US

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
<i>GW</i>	C29	GORSKI, J.; "Quantitation of Human Complement Fragment C4ai in Physiological Fluids by Competitive Inhibition Radioimmune Assay", <i>Journal of Immunological Methods</i> ; 1981, pp. 61-73, Vol. 47, Elsevier/North-Holland Biomedical Press.	
	C30	GOSLINGS W., et al.; "Membrane-Bound Regulators of Complement Activation in Uveal Melanomas. CD46, CD55, and CD59 in Uveal Melanomas"; <i>Investigative Ophthalmology &amp; Visual Science</i> , August 1996, pp. 1884-1891, Vol. 37, No. 8.	
	C31	GREEN, W.R.; "Histopathology of age-related macular degeneration", <i>Molecular Vision</i> , November 1999; Vol. 5, No. 27.	
	C32	GRIESINGER, I.B. et al; Macular Degeneration with Highly Variable Phenotype Localized to Chromosome 6q." <i>American Journal of Human Genetics</i> ; 63:A30; 1998, <i>ABSTRACT NO. 152</i>	
	C33	GURNE, D. et al; "Antiretinal Antibodies in Serum of Patients with Age-related Macular Degeneration", <i>Ophthalmology</i> , May 1991; pp. 602-607, Vol. 98, No. 5.	
	C34	HALLIDAY, W.J. and MALUISH, A.E.; Chapter 1: "Hemocytometer LAI: Immunological Basis and Applications", <i>Assessment of Immune Status by the Leukocyte Adherence Inhibition Test</i> ; 1982; pp. 1-26, Academic Press, Inc; New York	
	C35	HAYAMIZU et al; "Monocyte-derived dendritic cell precursors facilitate tolerance to heart allografts after total lymphoid irradiation", <i>Transplantation</i> , 1998, pp. 1285-1291, Vol. 66, No. 10	
	C36	HINTNER, H. et al; "Vitronectin Shows Complement-Independent Binding to Isolated Keratin Filament Aggregates", <i>Journal of Investigative Dermatology</i> , November 1989, pp. 656-661, Vol. 93, No. 5.	
	C37	HOLZ, F. et al.; "Patterns of increased in vivo fundus autofluorescence in the junctional zone of geographic atrophy of the retinal pigment epithelium associated with age-related macular degeneration.", <i>Graefes Arch Clin Exp Ophthalmol</i> ; 1999, pp. 145-52, Vol. 237.	
	C38	HUGLI, T.E. and CHENOWETH, D.E.; "Biologically Active Peptides of Complement: Techniques and Significance of C3a and C5a Measurements", <i>Immunoassays: Clinical Laboratory Techniques for the 1980s</i> ; 1980, pp. 443-460.	
	C39	INGLEHEARN, et al; Letter to the Editor entitled, "Loci for Autosomal Dominant Retinitis Pigmentosa and Dominant Cystoid Macular Dystrophy on Chromosome 7p Are Not Allelic", <i>American Journal of Human Genetics</i> ; 1994, pp. 581-582, Vol. 55.	
L	C40	JOHNSON, L.V. et al; "A Potential Role for Immune Complex Pathogenesis in Drusen Formation", <i>Exp Eye Res</i> , 2000; pp. 441-449, Vol. 70.	
	C41	KAKEHASHI, et al; "Differential Diagnosis of Macular Breaks By Microperimetry Using the Scanning Laser Ophthalmoscope", <i>Jpn J Ophthalmol</i> , 1996, pp. 116-122; Vol. 40, No. 1.	
	C42	KALUZNY, et al; "The use of indocyanine green angiography in diagnosis of occult choroidal neovascularization in age-related macular degeneration" (title translated), <i>Klinika Oczna</i> ; 1999, pp. 355-359, Vol. 101, No. 5, with abstract.	

Examiner Signature	<i>David A Laender</i>	Date Considered	<i>6/17/04</i>
--------------------	------------------------	-----------------	----------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

AUG 12 2003

PTO/SB/08B (10-01)

Approved for use through 10/31/2002, OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitution of Form 149B/PTO

INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet

5

of 9

Complete if Known

Application Number	10/084,639
Filing Date	February 25, 2002
First Named Inventor	Hageman, Gregory S., et. al.
Art Unit	1644
Examiner Name	Not yet assigned

Attorney Docket Number 020618-000920US

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS		
Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.
<i>David</i>	C43	KAZEEM, A.A. et al; "Assay of Circulating Immune Complexes by Immunonephelometry Markers of Immunonephropathy Among Young Nigerians", <i>East African Medical Journal</i> ; June 1990, pp. 396-403, Vol. 67, No. 6.
	C44	KELSELL, R. et al; Letter to the Editor entitled, "Localization of a Gene (CORD7) for a Dominant Cone-Rod Dystrophy to Chromosome 6q", <i>American Journal of Human Genetics</i> , 1998, pp. 274-279, Vol. 63.
	C45	KIANG, J. et al, "17 $\beta$ -Estradiol-induced Increases in Glucose-regulated Protein 78kD and 94kD Protect Human Breast Cancer T47-D Cells from Thermal Injury", <i>Chinese Journal of Physiology</i> ; 1997, pp. 213-219, Vol. 40, No. 4.
	C46	KILPATRICK, J. and VOLANAKIS, J.; "Opsonic Properties of C-Reactive Protein. Stimulation by Phorbolmyristate Acetate Enables Human Neutrophils to Phagocytize C-Reactive Protein-Coated Cells", <i>The Journal of Immunology</i> , May 1985, pp. 3364-3370, Vol. 134, No. 5.
	C47	KITA, T. et al; "Atherosclerosis V: The Fifth Saratoga International Conference. Oxidized-LDL and Atherosclerosis Role of LOX-1", <i>Annals of the New York Academy of Sciences</i> ; 2000, pp. 95-100, Vol. 902.
	C48	KLEIN, M. et al; "Age-Related Macular Degeneration. Clinical Features in a Large Family and Linkage to Chromosome 1q", <i>Arch. Ophthalmol</i> ; August 1998, pp. 1082-1088, Vol. 116.
	C49	KOHNO, T. et al; "Detection of Choroidal Neovascularization in Age-related Macular Degeneration Using Subtraction Methods in Indocyanine Green Angiography", <i>Bull Soc Belge Ophthalmol</i> ; 1995, pp. 81-88, Vol. 259.
	C50	KOPPI, T. and HALLIDAY, W.J.; "Further Characterization of the Cells Involved in Leukocyte Adherence Inhibition with Murine Tumor Extracts", <i>Cellular Immunology</i> , 1982; pp. 394-406, Vol. 66.
	C51	KOVACS, H. et al; "Evidence That C1q Binds Specifically to C12-like Immunoglobulin y Motifs Present in the Autoantigen Calreticulin and Interferes with Complement Activation", <i>Biochemistry</i> ; 1998, pp. 17865-17874, Vol. 37, No. 51.
	C52	KRAPF, F. et al; "Determination of Complement Activating Circulating Immune Complexes and an Example for Antigen Specific Immune Complex Assays", <i>Journal of Clinical Lab Immunology</i> ; 1988, pp. 183-187, Vol. 21.
	C53	KUCK, H. et al.; Diagnosis of Occult Subretinal Neovascularization in Age-related Macular Degeneration by Infrared Scanning Laser Videoangiography", <i>Retina</i> ; 1993, pp. 36-29, Vol. 13, No. 1.
	C54	KYLSTRA, J.A. et al; Letter to the Journal entitled, "Cone-rod retinal dystrophy in a patient with neurofibromatosis type 1", <i>Canadian Journal of Ophthalmology</i> ; 1993, pp. 79-80, Vol. 28, No. 2.
	C55	LANGLOIS, P. et al; "Plasma concentrations of complement-activation complexes correlate with disease activity in patients diagnosed with isolated central nervous system vasculitis", <i>Journal of Allergy Clinical Immunology</i> ; January 1989, pp. 11-18, Vol. 83, No. 1.
<i>David</i>	C56	LAWN et al; "The Sequence of Human Serum Albumin cDNA and Its Expression in E. coli", <i>Nucleic Acids Research</i> , 1981, pp. 6103-6114, Vol. 9, No. 22

Examiner  
Signature*David A. Sacchetti*Date  
Considered

6/17/04

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

DE 7089919 v1

O I P E JC154  
AUG 12 2003  
PATENT & TRADEMARK OFFICE  
U.S. GOVERNMENT

PTO/SB/08B (10-01)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 6 of 9

### Complete if Known

Application Number	10/084,639
Filing Date	February 25, 2002
First Named Inventor	Hageman, Gregory S., et. al.
Art Unit	1644
Examiner Name	Not yet assigned

Attorney Docket Number 020618-000920US

### OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
<i>DW</i>	C57	LI, X. et al.; "A pineal relulatory element (PIRE) mediates transactivation by the pineal/retina-specific transcription factor CRX", <i>Proc. Natl. Acad. Sci. USA</i> ; 1998, pp. 1876-1881, Vol. 95.	
	C58	LINDER, E. et al; "An Immunofluorescence Assay for Complement Activation by the Classical Pathway", <i>Journal of Immunological Methods</i> ; 1981, pp. 49-59, Vol. 47.	
	C59	LOTERY, A.J. et al; "Localisation of a Gene for Central Areolar Choroidal Dystrophy to Chromosome 17p", <i>Investigative Ophthalmology &amp; Visual Science</i> ; February 15, 1996; pp. 1124, Vol. 37, No. 3. (Abstract only)	
	C60	LUBINSKI, W. et al; "Foveal electroretinogram-application in diagnosis of macular diseases. Preliminary report.", <i>Klin Oczna</i> ; 1998, pp. 263-268, Vol. 100, No. 5. (Translated abstract of document included)	
	C61	LYNCH, N. et al; "Characterisation of the rat and mouse homologues of gC1qBP, a 33 kDa glycoprotein that binds to the globular 'heads' of C1q", <i>FEBS Letters</i> ; 1997, pp. 111-114, Vol. 418.	
	C62	MAHANT, S., et al.; "Retinal dystrophy in 18q- (de Grouchy) syndrome.", <i>Am. J. Hum. Genet.</i> ; 1995, p. A98, Vol. 57. (Abstract only) <i>ABSTRACT NO. 528</i>	
	C63	MARMORSTEIN, ALAN D., et al; "Bestrophin, the product of the Best vitelliform macular dystrophy gene (VMD2), localizes to the basolateral plasma membrane of the retinal pigment epithelium", <i>PNAS</i> ; November 7, 2000; pp. 12758-12763; Vol. 97, No. 23	
	C64	MARQUARDT, A. et al; "Mutations in a novel gene, VMD2, encoding a protein of unknown properties cause juvenile-onset vitelliform macular dystrophy (Best's disease)", <i>Human Molecular Genetics</i> ; 1998, pp. 1517-1525, Vol. 7, No. 9, Oxford University Press.	
	C65	MARX; "Testing of Autoimmune Therapy Begins", <i>Science</i> , April 1991, pp. 27-28, Vol. 252	
	C66	METZLER and WRAITH; "Inhibition of experimental autoimmune encephalomyelitis by inhalation but not oral administration of the encephalitogenic peptide: influence of MHC binding affinity", <i>International Immunology</i> , 1993, pp. 1159-1165, Vol. 5, No. 9	
	C67	MILIS, L. et al; "Vitronectin-mediated inhibition of complement: evidence for different binding sites for C5b-7 and C9", <i>Clin Exp Immunol.</i> ; 1993, pp. 114-119, Vol. 92.	
	C68	MINH, DO-QUANG et al; "Serial complement measurements in patients with leukaemia", <i>Clin Lab Haematol.</i> ; 1983, pp. 23-34, Vol. 5.	
	C69	MOLD, C. et al; "CR2 is a Complement Activator and the Covalent Binding Site for C3 During Alternative Pathway Activation by Raji Cells", <i>Journal of Immunology</i> ; March 15, 1988; pp. 1923-1929, Vol. 140, No. 6.	
<i>✓</i>	C70	MOUSA, S. et al. "Role of Hypoxia and Extracellular Matrix-Integrin Binding in the Modulation of Angiogenic Growth Factors Secretion by Retinal Pigmented Epithelial Cells", <i>Journal of Cellular Biochemistry</i> , 1999, pp. 135-143, Vol. 74	

Examiner Signature

*David A. Saunders*

Date Considered

*6/17/04*

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

DE 7089919 v1

O I P E  
AUG 12 2003  
PATENT & TRADEMARK OFFICE  
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

PTO/SB/08B (10-01)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO				Complete if Known	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>				Application Number	10/084,639
(use as many sheets as necessary)				Filing Date	February 25, 2002
				First Named Inventor	Hageman, Gregory S., et. al.
				Art Unit	1644
				Examiner Name	Not yet assigned
Sheet 7		of 9	Attorney Docket Number 020618-000920US		


OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS					
Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			T <sup>2</sup>
July	C71	MULLINS, R. et al.; "Drusen associated with aging and age-related macular degeneration contain proteins common to extracellular deposits associated with atherosclerosis, elastosis, amyloidosis, and dense deposit disease", <i>The FASEB Journal</i> ; May 2000, pp. 835-846, Vol. 14.			
	C72	MUNROE, P. et al; "Spectrum of Mutations in the Batten Disease Gene, CLN3", <i>American Journal of Human Genetics</i> ; 1987, pp. 310-318, Vol. 61.			
	C73	NEWELL, S., et al.; "Hemolytic and antigenic measurements of complement. A comparison of serum and plasma samples in normal individuals and patients"; <i>J Lab Clin Med</i> ; September 1982; pp. 437-444; Volume 100, No. 3.			
	C74	NG, Y.C. et al.; "Immune complexes and erythrocyte CR1 (complement receptor type 1): effect of CR1 numbers on binding and release reactions", <i>Clin Exp Immunol</i> ; 1988, pp. 481-485, Vol. 71.			
	C75	PADMA, T. and MURTY, J.S., "Association of Genetic Markers with Some Eye Diseases", <i>Acta Anthropogenetica</i> , 1983, pp. 1-12, Vol. 7, No. 1.			
	C76	PAYNE, A. et al; "A mutation in guanylate cyclase activator 1A (GUCA1A) in an autosomal dominant cone dystrophy pedigree mapping to a new locus on chromosome 6p21.1", <i>Human Molecular Genetics</i> ; 1998, pp. 273-277, Vol. 7, No. 2, Oxford University Press.			
	C77	PENFOLD, P. et al; "Autoantibodies to retinal astrocytes associated with age-related macular degeneration", <i>Graefe's Archive for Clinical and Experimental Ophthalmology</i> , 1990, pp. 270-274, Vol. 228.			
	C78	PINTÉR, C. et al; "Presence of autoantibodies against complement regulatory proteins in relapsing-remitting multiple sclerosis", <i>Journal of Neurology</i> ; 2000, pp. S42-S46, Vol. 6, Suppl. 2, Macmillan Publishers Ltd.			
	C79	QUAX-JEUKEN, Y. et al; " $\beta$ s-Crystallin: structure and evolution of a distinct member of the $\beta$ γ-superfamily", <i>EMBO Journal</i> , 1985, pp. 2597-2602, Vol. 4, No. 10.			
	C80	RABB, M. et al; "A North Carolina Macular Dystrophy Phenotype in a Belizean Family Maps to the MCDR1 Locus", <i>American Journal of Ophthalmology</i> , April 1998, pp. 502-508, Vol. 125, No. 4.			
	C81	RATNOFF, W. et al; "Immunohistochemical Localization of C9 Nocantigen and the Terminal Complement Inhibitory Protein CD59 in Human Endometrium", <i>American Journal of Reproductive Immunology</i> ; 1995, pp. 72-79, Vol. 34, Munksgaard, Copenhagen.			
	C82	RAVELLI, A. et al; "IgG autoantibodies to complement C1q in pediatric-onset systemic lupus erythematosus", <i>Clinical and Experimental Rheumatology</i> ; 1997, pp. 215-219, Vol. 15.			
	C83	REAVEN, PETER; "Mechanisms of Atherosclerosis: Role of LDL Oxidation", <i>Free Radicals in Diagnostic Medicine</i> , 1994, pp. 113-128, Plenum Press, New York, U.S.A.			
	C84	RODRICK, M. et al; "An Evaluation of Two Antigen Nonspecific Assays for Circulating Immune Complexes Using an Model System", <i>J. Clin Lab Immunol</i> , 1982, pp. 193-198, Vol. 7, No. 3.			

Examiner Signature	David A Saenders	Date Considered	6/17/04
--------------------	------------------	-----------------	---------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



Substitute for form 1449B/PTO

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet

8

of

9

Complete if Known	
Application Number	10/084,639
Filing Date	February 25, 2002
First Named Inventor	Hageman, Gregory S., et. al.
Art Unit	1644
Examiner Name	Not yet assigned
Attorney Docket Number	020618-000920US

+

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS		
Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.
GW	C85	SACKS, J.G. et al; "The Pathogenesis of Optic Nerve Drusen", <i>Archives of Ophthalmology</i> , March 1997, pp. 425-428, Vol. 95, No. 3.
	C86	SEYMOUR, A. et al; "Linkage Analysis of X-linked Cone-Rod Dystrophy: Localization to Xp11.4 and Definition of a Locus Distinct from RP2 and RP3", <i>Am. J. Hum. Genet.</i> ; 1998, pp. 122-129, Vol. 62.
	C87	SLINGSBY, C. and BATEMAN, O.A.; "Rapid Separation of Bovine $\beta$ -Crystallin Subunits $\beta$ B1, $\beta$ B2, $\beta$ B3, $\beta$ A3 and $\beta$ A4", <i>Exp Eye Res</i> , 1990, pp. 21-26, Vol. 51.
	C88	SMALL, K. et al.; "Mapping of Autosomal Dominant Cone Degeneration to Chromosome 17p", <i>American Journal of Ophthalmology</i> , 1998, pp. 13-18, Vol. 121, No. 1.
	C89	SPRAUL, et al; "Optical Coherence Tomography of Age-Related Macular Degeneration. Correlation of Diagnostic Techniques of Fluorescence angiography and OCT" (title translated) <i>Klin Monatsbl Augenheilkd</i> , March 1998, pp. 141-148, Vol. 212. <i>SUMMARY ONLY</i>
	C90	STONE, EDWIN M., et al.; "A single EFEMP1 mutation associated with both Malattia Leventinese and Doyne honeycomb retinal dystrophy", <i>Nature Genetics</i> ; June 1999; pp. 199-202; Volume 22.
	C91	STRIFE, C. et al; "Autoantibody to complement neoantigens in membranoproliferative glomerulonephritis", <i>The Journal of Pediatrics</i> ; May 1990, pp. S98-S102, Vol. 116, No. 5.
	C92	SUZUKI et al.; "Complete amino acid sequence of human vitronectin deduced from cDNA. Similarity of cell attachment sites in vitronectin and fibronectin", <i>EMBO J</i> , 1985, pp. 2519-2524, Vol. 4, No. 10
	C93	TANAKA, S. et al; "Assay of classical and alternative pathway activities of murine complement using antibody-sensitized rabbit erythrocytes", <i>Journal of Immunological Methods</i> ; 1986, pp. 161-170, Vol. 86, Elsevier Science Publishers B.V.
	C94	THOMSON et al; "Microchimerism, Dendritic Cell Progenitors and Transplantation Tolerance", <i>Stem Cells</i> ; 1995, pp. 622-639, Vol. 13
	C95	TOMIMORI-YAMASHITA, J. et al; "Antibody-based enzyme-linked immunosorbent assay for determination of anti-PGL-I specific circulating immune complex in leprosy patients.", <i>Lepr Rev</i> ; 1999, pp. 261-271, Vol. 70.
	C96	TRAN, H. et al; "Human Fibulin-1D: Molecular Cloning, Expression and Similarity with S1-5 Protein, a New Member of the Fibulin Gene Family", <i>Matrix Biology</i> , 1997, pp. 479-493, Vol. 15
	C97	TRENTHAM et al; "Effects of Oral Administration of Type II Collagen on Rheumatoid Arthritis", <i>Science</i> ; 1993, pp. 1727-1730, Vol. 261
↓	C98	TSCHOPP, J. et al; "Clusterin, the Human Apolipoprotein and Complement Inhibitor, Binds to Copelement C7, C8 $\beta$ , and the b Domain of C9", <i>Journal of Immunology</i> ; August 15, 1993; pp. 2159-2165, Vol. 151, No. 4, Printed in the U.S.A.

Examiner Signature	<i>David J. Haenle</i>	Date Considered	6/17/04
--------------------	------------------------	-----------------	---------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

AUG 12 2003

PTO/SB/08B (10-01)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 9 of 9

Complete if Known	
Application Number	10/084,639
Filing Date	February 25, 2002
First Named Inventor	Hageman, Gregory S., et. al.
Art Unit	1644
Examiner Name	Not yet assigned
Attorney Docket Number	020618-000920US

## OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
<i>Daryl</i>	C99	VAN DIJK, H. et al.; "Determination of Alternative Pathway of Complement Activity in Mouse Serum Using Rabbit Erythrocytes", <i>Journal of Immunological Methods</i> , 1890, pp.29-39, Vol. 36, Elsevier/North-Holland Biomedical Press.	
	C100	VOLANAKIS, J.; C-Reactive Protein and the Plasma Protein Response to Tissue Injury. Part IV. Biological Properties and Function of CRP and SAP: "Complement Activation by C-Reactive Protein Complexes", <i>Annals of the New York Academy of Sciences</i> ; 1982, pp. 235-50, Vol. 389.	
	C101	WARBURG, M., et al; "Deletion Mapping of a Retinal Cone-Rod Dystrophy: Assignment to 18q211", <i>American Journal of Medical Genetics</i> ; 1991, pp. 288-293, Vol. 39.	
	C102	WEXLER et al; "Primary amino acid sequence and structure of human pyruvate carboxylase", <i>Biochimica et Biophysica Acta</i> , 1994, pp. 46-52, Vol. 1227	
	C103	YAMANAKA, R. et al; "CCAAT/enhancer binding protein $\epsilon$ is preferentially up-regulated during granulocytic differentiation and its functional versatility is determined by alternative use of promoters and differential splicing.", <i>Proc Natl Acad Sci USA</i> ; June 1997, pp. 6462-6467, Vol. 94.	
	C104	YUZAWA, M. et al; "Clinical evaluation of indocyanine green video-angiography in the diagnosis of choroidal neovascular membrane associated with age-related macular degeneration", <i>European Journal of Ophthalmology</i> ; 1992, pp. 115-121, Vol. 2, No. 3.	
	C105	ZHANG, K. et al; "A dominant Stargardt's Macular Dystrophy Locus Maps to Chromosome 13q34", <i>Arch. Ophthalmol.</i> ; June 1994, pp. 759-764, Vol. 112.	
<i>Daryl</i>	C106	ZHANG, Y. et al; "Lysis via the lectin pathway of complement activation: minireview and lectin pathway enhancement of endotoxin-initiated hemolysis", <i>Immunopharmacology</i> , May 1999; pp. 81-90; Volume 42	

Examiner Signature	<i>Daryl A facemire</i>	Date Considered	6/17/04
--------------------	-------------------------	-----------------	---------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

DE 7089919 v1



Substitute for form 1449A/PTO				<i>Complete if Known</i>	
				Application Number	10/084,639
				Filing Date	February 25, 2002
				First Named Inventor	Hageman, Gregory S.
				Art Unit	1644
				Examiner Name	Not yet assigned
Sheet	1	of	5	Attorney Docket Number	020618-000920US

U.S. PATENT DOCUMENTS+						
Examiner Initials*	Cite No. <sup>1</sup>	Document Number		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code <sup>2</sup> (if known)			
dag	A1	US-5,686,598		11-11-1997	North et al.	
	A2	US 5,705,380		01-06-1998	North et al.	
	A3	US 2002-0102581 A1		8-1-2002	Hageman et al.	
	A4	US 2003-0207309 A1		11-6-2003	Hageman et al.	

FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document			Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Country Code <sup>3</sup>	Number <sup>4</sup>	Kind Code <sup>5</sup> (if known)				
dag	B1	PCT	WO 97/38004	A1	10-16-1997			<input type="checkbox"/>
	B2							<input type="checkbox"/>

Examiner Signature	<i>David A. Saunders</i>	Date Considered	<i>6/18/04</i>
--------------------	--------------------------	-----------------	----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Kind Codes of U.S. Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>3</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>4</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>5</sup> Applicant is to place a check mark here if English language Translation is attached.

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet

2

of

5

Application Number	10/084,639
Filing Date	February 25, 2002
First Named Inventor	Hageman, Gregory S.
Art Unit	1644
Examiner Name	Not yet assigned

Attorney Docket Number

020618-000920US

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
<i>DJS</i>	C1	Bird, A. "Age-related macular disease," Br. J. Ophthalmol., 80, 2-3, 1996.	
	C2	Bird, A. "Bruch's membrane change with age," Br. J. Ophthalmol., 763, 166-168, 1992.	
	C3	Bressler, N., et al. "Clinicopathologic correlation of drusen and retinal pigment epithelial abnormalities in age-related macular degeneration," Retina, 14, 130-142, 1994.	
	C4	Bressler, S., et al. "Relationship of drusen and abnormalities of the retinal pigment epithelium to the prognosis of neovascular macular degeneration," Arch. of Ophthalmol., 108, 1442-1447, 1990.	
	C5	Burns, R., and Feeney-Burns, L., Transactions of the American Ophthalmologic Society, 78, 206-225, 1980.	
	C6	CHEN, H. et al. "An immunologic study of age-related macular degeneration" Yan Ke Xue Bao, Sept. 1993, pp. 113-120, Vol. 9, No. 3	
	C7	De La Paz, M., et al. "Analysis of the stargardt disease gene (ABCR) in age-relate macular degeneration," Invest. Ophthalmol. Vis. Sci. (Suppl), 39, S915, 1980. ABSTRACT NO. 4213	
	C8	Duvall, J., and Tso, M. "Cellular mechanisms of resolution of drusen after laser coagulation," Arch. Ophthalmol., 103, 694-703, 1985.	
	C9	Duvall-Young, J., et al. "Fundus changes in (type II) mesangiocapillary glomerulonephritis simulating drusen: a histopathological report," Br. J. Ophthalmol., 73, 297-302, 1989.	
	C10	Eagle, R. "Mechanisms of maculopathy," Ophthalmol., 91, 613-25, 1984.	
	C11	Eisner, A., et al. "Sensitivities in older eyes with good acuity: eyes whose fellow eye has exudative AMD," Invest. Ophthalmol. Vis. Sci., 28, 1832-1837, 1987.	
	C12	Elman, M., and Fine, S. "Exudative age-related macular degeneration," in S. Ryan (Ed.), The Retina (pp. 175-200). St Louis: CV Mosby, 1992.	
	C13	Esser et al. "The significance of vitronectin in proliferative diabetic retinopathy," Graefes Archive for Clinical and Experimental Ophthalmology, 232 (8) 477-81, 1994.	
	C14	Farkas, T., et al. "The histochemistry of drusen," Amer. J. Ophthalmol., 71, 1206-1215, 1971.	
	C15	Farkas, T., et al. The ultrastructure of drusen," Amer. J. Ophthalmol., 71, 1196-1205, 1971.	
<i>✓</i>	C16	Feeney-Burns, et al. "Lysosomal enzyme cytochemistry of human RPE, bruch's membrane and drusen," Invest. Ophthalmol. Vis. Sci., 28, 1138-1147, 1987.	

Examiner Signature

*David A Saunders*

Date Considered

6/11/04

<sup>1</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>2</sup> Applicant's unique citation designation number (optional). <sup>3</sup> Applicant is to place a check mark here if English language Translation is attached.

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet	3	of	5	Attorney Docket Number	020618-000920US
-------	---	----	---	------------------------	-----------------

## NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	C17	Feeney-Burns, L. et al. "The fate of immunoreactive opsin following phagocytosis by pigment epithelium in human and monkey retinas," Invest. Ophthalmol. Vis. Sci., 29, 708-719, 1988.	
	C18	Feeney-Burns, L., and Ellersieck, M. "Age-related changes in the ultrastructure of bruch's membrane," Amer. J. Ophthalmol., 100, 686-697, 1985.	
	C19	Frennesson, I., and Nilsson, S. "Laser photocoagulation of soft drusen in early age-related maculopathy (ARM). The one-year results of a prospective , randomised trial," Eur. J. Ophthalmol., 6, 307-314, 1996.	
	C20	Frennesson, C., et al. "Colour contrast sensitivity in patientswith soft drusen, an early stage of ARM, ", Documenta Ophthalmologica, 90, 377-86, 1995.	
	C21	Grossiklaus, et al. " Immunohistochemical and histochemical properties of surgically excised subretinal neovascular membranes in age-related macular degeneration," American Journal of Ophthalmology 114 (4), 464-72, 1992.	
	C22	Hageman, et al. " Vitronectin is a constituent of ocular drusen and the vitronectin gene is expressed in human retinal pigmented epithelial cells," FASEB Journal, 13(3), 477-84, 1999.	
	C23	Heidenkummer, et al. "Surgical extraction of subretinal pseudotumors in age related macular degeneration," Ophthalmologe, 92 (5), 631-639, 1995. <i>SUM MAR, ONL</i>	
	C24	Holz, F., et al. "Analysis of lipid deposits extracted from human macular and peripheral bruch's membrane," Arch. Ophthalmol., 112, 402-406, 1994.	
	C25	Ishibashi, T., et al. "Formation of drusen in the human eye," Amer. J. Ophthalmol., 101, 342-353, 1986.	
	C26	Ishibashi, T., et al. "Pathogenesis of drusen in the primate," Invest. Ophthalmol. Vis. Sci., 27, 184-193, 1986.	
	C27	KELTNER, JL & THIRKILL, CE "The 22-kDa antigen in optic nerve and retinal diseases" J. Neuroophthalmol., June 1999, pp. 71-83, Vol. 19, No. 2.	
	C28	Killingsworth, M., et al. "Macrophages related to bruch's membrane in age-related macular degeneration," Eye, 4, 613-621, 1990.	
	C29	Klaver et al., "Genetic association of apolipoprotein E with age-related macular degeneration," Am J. of Human Genetics, 63 (1), 200-6, 1998.	
	C30	Lewis, H., et al. "Chorioretinal Juncture, multiple extramacular drusen," Ophthalmol., 93, 1098-1112, 1986.	
	C31	Loeffler, K., and Mangini, M. "Immunolocalization of ubiquitin and related enzymes in human retina and retinal pigment epithelium," Graefe's Arch. Clin. Exp. Ophthalmol., 235, 248-54, 1997.	
	C32	Loeffler, K., et al. "Immunoreactivity against tau, amyloid precursor protein, and beta-amyloid in the human retina," Invest. Ophthalmol. Vis. Sci., 36, 24-31, 1995.	

Examiner Signature	<i>David A Saunders</i>	Date Considered	6/17/04
--------------------	-------------------------	-----------------	---------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(use as many sheets as necessary)</i>				Application Number	10/084,639
				Filing Date	February 25, 2002
				First Named Inventor	Hageman, Gregory S.
				Art Unit	1644
				Examiner Name	Not yet assigned
				Sheet	4

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
<i>David</i>	C33	Midéna, E., et al. "Macular function impairment in eyes with early age-related macular degeneration," Invest. Ophthalmol. Vis. Sci., 38, 469-477, 1997.	
	C34	Newsome, D., et al. "Detection of specific extracellular matrix molecules in drusen, bruch's membrane and ciliary body," Amer. J. Ophthalmol., 104, 373-381, 1987.	
	C35	Newsome, D., et al. "Macular degeneration and elevated serum ceruloplasmin," Invest. Ophthalmol. Vis. Sci., 27, 1675-80, 1986.	
	C36	Pauleikhoff, D., et al. "Drusen as risk factors in age-related macular disease," Amer. J. Ophthalmol., 109, 38-43, 1990.	
	C37	Pauleikhoff, D., et al. "Correlation between biochemical composition and fluorescein binding of deposits in bruch's membrane," Ophthalmol., 99, 1548-1553, 1992.	
	C38	PENFOLD, P. et al. "Modulation of major histocompatibility complex II expression in retinas with age-related macular degeneration," Invest. Ophthalmol. Vis. Sci., 38, 2125-33, 1997.	
	C39	PENFOLD, P. et al. "Senile macular degeneration," Invest. Ophthalmol. Vis. Sci., 27, 364-71, 1986.	
	C40	PENFOLD, P. et al. "Senile macular degeneration: the involvement of immunocompetent cells," Graefe's Arch. Clin. Exp. Ophthalmol., 223, 69-76, 1985.	
	C41	Sarks, J., et al. "Evolution of soft drusen in age-related macular degeneration" (1994), Eye, 8, 269-283.	
	C42	Sarks, S. "Aging and degeneration in the macular region: a clinico-pathological study," Br. J. Ophthalmol., 60, 324-341, 1976.	
	C43	Sarks, S. "Drusen and their relationship to senile macular degeneration," Aust. J. Ophthalmol., 8, 117-30, 1980.	
	C44	Sarks, S. "Drusen patterns predisposing to geographic atrophy of the retinal pigment epithelium," Austr. J. Ophthalmol., 10, 91-97, 1982.	
	C45	Sarks, S., and Sarks, J. "Age-related macular degeneration: atrophic form," in S. Ryan (Ed.), The Retina St. Louis: CV Mosby, 1989.	
	C46	Sarks, S., et al. , Patterns in macular degeneration. In S. Ryan, A. Dawson, and H. Little (Eds.), Retinal Diseases (pp. 87-93). Orlando: Grune and Stratton, 1985.	
	C47	Sarks, S., et al. "Softening of drusen and subretinal neovascularization," Trans. Ophthalmol. Soc. U.K., 100, 414-422, 1980.	
<i>✓</i>	C48	Sokal, I. et al. "GCAP1(Y99C) mutant is constitutively active in autosomal dominant cone dystrophy," Mol. Cell. 2:129-133, 1998.	

Examiner Signature	<i>David A. Seenderus</i>	Date Considered	<i>6/17/04</i>
--------------------	---------------------------	-----------------	----------------

<sup>1</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>2</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet	5	of	5	Attorney Docket Number	020618-000920US
-------	---	----	---	------------------------	-----------------

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
<i>dsf</i>	C49	Souied, et al. "The epsilon4 allele of the apolipoprotein E gene as a potential protective factor for exudative age-related macular degeneration," Am. J. of Ophthalmology, 125 (3) 353-9, 1998.	
	C50	Spraul, C., and Grossniklaus, H. "Characteristics of drusen and bruch's membrane in postmortem eyes with age-related macular degeneration," Arch. Ophthalmol., 115, 267-73, 1997.	
	C51	TSO, MO "Experiments on visual cells by nature and man: in search of treatment for photoreceptor degeneration. Friedenwald lecture." Invest Ophthalmol Vis Sci, Dec 1989, pp. 2430-2454, Vol. 30, No. 12.	
	C52	van der Schaft, T., et al. "Early stages of age-related macular degeneration: an immunofluorescence and electron microscopy study," Br. J. Ophthalmol., 77, 657-661, 1993.	
	C53	Vinding, T. "Occurrence of drusen, pigmentary changes and exudative changes in the macula with reference to age-related macular degeneration," Acta Ophthalmologica, 68, 410-414, 1990.	
	C54	Young, R. "Pathophysiology of age-related macular degeneration" Surv. Ophthalmol., 31, 291-306, 1987.	

Examiner Signature	<i>David Saunders</i>	Date Considered	<i>6/7/04</i>
--------------------	-----------------------	-----------------	---------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.